FGFR1 and breast carcinoma: However, despite the clear rationale for targeting FGFR1 in breast cancer with inhibitors, none have, to date, achieved an objective response, and this could be a consequence of inadequate patient selection and/or that FGFR1 may not be the only oncogenic driver in the 8p11-12 amplicon.